Listen to CLiC Podcast Episode #3: Dr. Versha Banerji reviews the Phase III Alliance A041202 results on ibrutinib alone or with rituximab as front-line therapy in older CLL patients (11:20)

~ cliccommunity

CLiC Podcast Episode #3: Dr. Versha Banerji reviews the Phase III Alliance A041202 results on ibrutinib alone or with rituximab as front-line therapy in older CLL patients (11:20)

 

CLiC Poll #2: Survey re. MURANO 48-month data presented at iwCLL conference 2019

~ cliccommunity

On behalf of the CLiC Leaders, we invite you to participate in the following poll. Click here to answer.

Note that the following questions refer to the MURANO 48-month data presented at iwCLL conference 2019, reviewed in Dr. Carolyn Owen’s podcast available here.

1. Based on the MURANO 48-month data presented at iwCLL conference 2019, reviewed in Dr. Owen’s podcast, should MRD testing (positive MRD) be used to tailor treatment with VR given 27% of patients who discontinued treatment have now progressed?

  • Yes
  • No
  • Maybe

2. Based on the MURANO 48-month data, should high risk cytogenetics be used to tailor treatment with VR given 27% of patients who discontinued treatment have now progressed?

  • Yes
  • No
  • Maybe
3. Based on the MURANO 48-month data, should everyone stop treatment at 24 months?
  • Yes
  • No
  • Maybe

Click here to answer

CLiC Webinar on Tuesday, Oct 29 at 7:00 pm ET: Join CLiC leaders to review key questions in CLL

~ cliccommunity

Please join CLiC scientific committee leaders Dr. Carolyn Owen and Dr. Versha Banerji for a webinar to review the poll, podcasts and discussion in the CLiC community in 2019 (see below).

The webinar is open to all CLiC members and is scheduled for Tuesday, Oct 29, 2019, 7:00 pm EST. See connection instructions below:

Step 1: To join the audio portion dial toll-free 1-866-830-9434 and enter participant code 7994216

Step 2: To join the web portion, click on this link and enter as a guest: https://studio7communications.adobeconnect.com/clic_29oct2019/
Prior to the webinar, you are invited to participate and review the following:

  • CLiC Poll: Excluding patients with del(17p)/TP53 mutation, which patients should be receiving chemo-immunotherapy firstline for CLL today? [view & vote]
  • CLiC Podcast Episode #1: Dr. Carolyn Owen reviews the CLL14 Clinical Trial (6:43) [listen]
  • CLiC Podcast Episode #2: Dr. Carolyn Owen reviews the MURANO study data at 48 months as presented at the International Workshop on Chronic Lymphocytic Leukaemia (iwCLL) meeting held Sep 2019 in Edinburgh (4:10) [listen]
  • CLiC Discussion: Regarding MURANO 48-month data presented at iwCLL conference 2019, reviewed in Dr. Owen’s podcast: (1) Should MRD testing (positive MRD) be used to tailor treatment with VR given 27% of patients who discontinued treatment have now progressed? (2) Should high risk cytogenetics be used to tailor treatment with VR given 27% of patients who discontinued treatment have now progressed? (3) Should everyone stop treatment at 24 months? [view & discuss]

The webinar will be recorded and archived for future viewing by the CLiC community.

 

Listen to CLiC Podcast Episode #2: Dr. Carolyn Owen reviews the MURANO study data at 48 months as presented at the International Workshop on Chronic Lymphocytic Leukaemia (iwCLL) meeting held Sep 2019 in Edinburgh (4:10)

~ cliccommunity

CLiC Podcast Episode #2: Dr. Carolyn Owen reviews the MURANO study data at 48 months as presented at the International Workshop on Chronic Lymphocytic Leukaemia (iwCLL) meeting held Sep 2019 in Edinburgh (4:10)

 

CLiC Poll #1: Excluding patients with del(17p)/TP53 mutation, which patients should be receiving chemo-immunotherapy firstline for CLL today?

~ cliccommunity

If you haven’t yet participated in the poll, we invite you to share your views on Chemo-Immunotherapy for CLL:

Excluding patients with del(17p)/TP53 mutation, which patients should be receiving chemo-immunotherapy firstline for CLL today?

  • None – every patient should be receiving novel agents firstline today
  • Only young, fit with mutated IgVH who are eligible for curative-intent FCR
  • All patients except young and fit with unmutated IgHV
  • All patients firstline

Click here to answer